rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
5
|
pubmed:dateCreated |
2004-2-12
|
pubmed:abstractText |
To examine the clinical effectiveness and cost-effectiveness of oral capecitabine for locally advanced and metastatic breast cancer in relation to its licensed indications.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1366-5278
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
iii, xiii-xvi, 1-143
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:14960257-Administration, Oral,
pubmed-meshheading:14960257-Antimetabolites, Antineoplastic,
pubmed-meshheading:14960257-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14960257-Breast Neoplasms,
pubmed-meshheading:14960257-Cost-Benefit Analysis,
pubmed-meshheading:14960257-Deoxycytidine,
pubmed-meshheading:14960257-Disease Progression,
pubmed-meshheading:14960257-Drug Therapy, Combination,
pubmed-meshheading:14960257-Female,
pubmed-meshheading:14960257-Fluorouracil,
pubmed-meshheading:14960257-Great Britain,
pubmed-meshheading:14960257-Humans,
pubmed-meshheading:14960257-Neoplasm Metastasis,
pubmed-meshheading:14960257-Quality-Adjusted Life Years,
pubmed-meshheading:14960257-Randomized Controlled Trials as Topic,
pubmed-meshheading:14960257-State Medicine,
pubmed-meshheading:14960257-Survival Rate,
pubmed-meshheading:14960257-Taxoids,
pubmed-meshheading:14960257-Treatment Outcome
|
pubmed:year |
2004
|
pubmed:articleTitle |
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
|
pubmed:affiliation |
NHS Centre for Reviews and Dissemination, University of York, UK.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Review
|